How much revenue does 3D Medicines make?

3D Medicines reported 356.09 million CNY in revenue for fiscal year 2025, down 20.1% from 445.65 million CNY in fiscal year 2024.

What companies are similar to 3D Medicines?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Jacobio-b (1167.HK), Immuneonco-b (1541.HK), Sunho Biologics, Inc. (2898.HK), Wuhan YZY Biopharma Co., Ltd. (2496.HK).

3D Medicines (1244.HK) Stock

About 3D Medicines

3D Medicines Inc., a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products in the People's Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is al...

At a glance

3D Medicines reported revenue of 356.09 million CNY for fiscal year 2025, down 20.1% from fiscal year 2024, and net income of -177.53 million CNY.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.